One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy

Authors

  • Raphaël Briffaux,

    1. CHU La Milétrie, Poitiers, *Centre Hospitalier René Dubos, Pontoise, CHU Bretonneau, Tours, and Centre Hospitalier Saint Louis, La Rochelle, France
    Search for more papers by this author
  • Patrick Coloby,

    1. CHU La Milétrie, Poitiers, *Centre Hospitalier René Dubos, Pontoise, CHU Bretonneau, Tours, and Centre Hospitalier Saint Louis, La Rochelle, France
    Search for more papers by this author
  • Franck Bruyere,

    1. CHU La Milétrie, Poitiers, *Centre Hospitalier René Dubos, Pontoise, CHU Bretonneau, Tours, and Centre Hospitalier Saint Louis, La Rochelle, France
    Search for more papers by this author
  • Frédéric Ouaki,

    1. CHU La Milétrie, Poitiers, *Centre Hospitalier René Dubos, Pontoise, CHU Bretonneau, Tours, and Centre Hospitalier Saint Louis, La Rochelle, France
    Search for more papers by this author
  • Christophe Pires,

    1. CHU La Milétrie, Poitiers, *Centre Hospitalier René Dubos, Pontoise, CHU Bretonneau, Tours, and Centre Hospitalier Saint Louis, La Rochelle, France
    Search for more papers by this author
  • Bertrand Doré,

    1. CHU La Milétrie, Poitiers, *Centre Hospitalier René Dubos, Pontoise, CHU Bretonneau, Tours, and Centre Hospitalier Saint Louis, La Rochelle, France
    Search for more papers by this author
  • Jacques Irani

    1. CHU La Milétrie, Poitiers, *Centre Hospitalier René Dubos, Pontoise, CHU Bretonneau, Tours, and Centre Hospitalier Saint Louis, La Rochelle, France
    Search for more papers by this author

Jacques Irani, Departement d’Urologie, Centre Hospitalier Universitaire La Miletrie, 86000, Poitiers, France.
e-mail: j.irani@chu-poitiers.fr

Abstract

OBJECTIVE

To compare the incidence of infective events between a single dose and 3-day antibiotic prophylaxis for transrectal ultrasonography (TRUS)-guided prostate biopsy.

PATIENTS AND METHODS

Patients were randomized to receive either one preoperative dose consisting of two ciprofloxacin 500 mg tablets 2 h before prostate biopsy, or 3 days of ciprofloxacin treatment. They had a clinical examination at study inclusion, the day of the biopsy and 3 weeks later. The day after the procedure all patients were contacted by telephone to inquire about any significant event. Biological testing and urine cultures were conducted 5 days before and then 5 and 15 days after the biopsy; a self-administered symptom questionnaire was completed by the patient 5 days before and then at 5 and 15 days.

RESULTS

The study group included 288 men, of whom 139 were randomized to the single-dose arm and 149 to the 3-day arm. Six patients in each group had an asymptomatic bacteriuria with no leukocyturia. One patient in each group had documented prostatitis, with Escherichia coli identified on urine culture. The strain identified in the patient from the 3-day group was resistant to ciprofloxacin. There was no difference between groups in symptoms at 5 and 21 days after biopsy.

CONCLUSIONS

Current TRUS-guided prostate biopsy techniques lead to very few clinical infectious complications when accompanied by antibiotic prophylaxis. We found no argument to advocate the use of more than one dose of antibiotic prophylaxis.

Ancillary